Comparative Pharmacology
Head-to-head clinical analysis: BIPHETAMINE 20 versus BIPHETAMINE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIPHETAMINE 20 versus BIPHETAMINE 7 5.
BIPHETAMINE 20 vs BIPHETAMINE 7.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphetamine 20 is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, and inhibit their reuptake, thereby increasing synaptic concentrations of these neurotransmitters in the central nervous system.
Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.
10-20 mg orally once daily in the morning; may increase to 20 mg twice daily (morning and noon) if needed.
Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.
None Documented
None Documented
0.5–1.5 hours for the immediate-release component; terminal elimination half-life of the total amphetamine salts is approximately 10–13 hours in adults
6-8 hours (amphetamine moiety), 10-13 hours (dextroamphetamine); clinical effects may outlast serum levels due to accumulation.
Renal (90% as unchanged drug and metabolites, with approximately 30% unchanged); fecal (10%)
Renal: ~70-90% unchanged and as active metabolites; minor fecal elimination. Acidic urine (pH <5.6) increases excretion; alkaline urine (pH >7.0) decreases it.
Category C
Category C
Central Nervous System Stimulant
Central Nervous System Stimulant